Advertisement

Quality of Life Research

, Volume 5, Issue 5, pp 491–495 | Cite as

Assessment of the RSCL quality of life instrument during chemotherapy in an Italian setting

  • A. Ravaioli
  • P. Buda
  • C. Fava
  • E. Paci
  • A. Tononi
  • N. Riva
  • M. Zanotti
  • G. Drudi
Research Papers

Abstract

Evaluation of the quality of life of oncological patients is now perceived as a major element of cancer treatment, and various instruments for measuring it have been proposed. However, whatever instrument is used must be capable of reflecting the different ways in which different contexts and cultures respond to cancer. We administered the Italian version of the Rotterdam Symptom Checklist (RSCL) to 60 patients with advanced disease attending five oncological centres in Romagna (central Italy). The RSCL was found to be able to measure both psychological and physical well-being and to detect a difference between patients on low/medium and those on high-burden chemotherapy. The Italian version of the RSCL is an adequate scale that is capable of capturing patient perceptions and could be used for monitoring the quality of life of Italian patients participating in clinical trials.

Key words

Advanced cancer patients chemotherapy quality of life Rotterdam Symptoms Checklist 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Donovan K, Sanson-Fisher RW, Redman S. Measuring quality of life in cancer patients. J Clin Oncol 1989; 7: 959–968.Google Scholar
  2. 2.
    Grant M, Padilla GV, Ferell BR et al. Assessment of quality of life with a single instrument. Sem Oncol Nursing 1990; 6: 260–270.Google Scholar
  3. 3.
    Maiguire P, Selby P. Assessing quality of life in cancer patients. Br J Cancer 1989; 60: 437–440.Google Scholar
  4. 4.
    Priestman TJ, Baum M. Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet 1976; 24: 899–900.Google Scholar
  5. 5.
    Hopwood P, Howell A, Maguire P. Screening for psychiatric morbidity in patients with advanced breast cancer: validation of two self-reported questionnaires. Br J Cancer 1991; 64: 353–356.Google Scholar
  6. 6.
    Hopwood P, Howell A, Maigure P. Psychiatric morbidity in patients with advanced cancer of breast: prevalence measured by two self-rating questionnaires. Br J Cancer 1991; 64: 349–352.Google Scholar
  7. 7.
    Jones DR, Fayers PM, Simons J. Measuring and analyzing quality of life in cancer clinical trials: a review. In: Aaronson NK, Beckmann J, eds. The Quality of Life of Cancer Patients. New York: Raven Press, 1987: 41–61.Google Scholar
  8. 8.
    McMillen Mainpour C, Feigl P, Metch B et al. Quality of life and points in cancer clinical trials: review and recommendations. J Natl Cancer Inst 1989; 81: 485–495.Google Scholar
  9. 9.
    Schipper H, Clinch J, McMurray A, et al. Measuring the quality of life of cancer patients: the functional living index—cancer development and validation. J Clin Oncol 1984; 2: 472–483.Google Scholar
  10. 10.
    Spitzer WO. State of science 1986: quality of life and functional status as target variables for research. J Chron Dis 1987; 40: 465–471.Google Scholar
  11. 11.
    Tamburini M, Brambilla C, Ferrari L, et al. Two simple indexes used to evaluate the impact of therapy on the quality of life of patients receiving primary chemotherapy for operable breast cancer. Ann Oncol 1991; 2: 417–422.Google Scholar
  12. 12.
    De Haes JCJM, Van Knippenberg FCE, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990; 62: 1034–1038.Google Scholar
  13. 13.
    Paci E. Assessment of validity and clinical application of an Italian version of the Rotterdam Symptom Checklist. Qual Life Res 1992; 1: 129–134.Google Scholar
  14. 14.
    Richard MA, Hopwood P, Ramires AJ, et al. Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life. Eur J Cancer 1992; 28A: 1023–1028.Google Scholar
  15. 15.
    Soukap M, Mc Quade B, Hunter E, et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncol 1992; 49: 295–304.Google Scholar

Copyright information

© Rapid Science Publishers 1996

Authors and Affiliations

  • A. Ravaioli
    • 1
  • P. Buda
    • 1
  • C. Fava
    • 1
  • E. Paci
    • 2
  • A. Tononi
    • 1
  • N. Riva
    • 3
  • M. Zanotti
    • 4
  • G. Drudi
    • 1
  1. 1.Department of OncologyCivil HospitalRiminiItaly
  2. 2.C.S.P.O.FirenzeItaly
  3. 3.Department of OncologyCivil HospitalForlìItaly
  4. 4.Department of OncologyCivil HospitalRavennaItaly

Personalised recommendations